NeoStem forges licensing deal to start Phase II study in China

NeoStem (NBS) has signed a licensing agreement with China-based Cellular Biomedicine Group (CBMG) to begin a Phase 2 trial of NeoStem's DC-TC immunotherapy in patients with late-stage liver cancer.

NeoStem will receive $1M when the first patient is enrolled in the study - which will take place in China - and up to $30M in milestone fees over the lifetime of the agreement, as well as royalties and sub-license payments. CBMG will also pay for the trial and take responsibility for clinical, marketing and commercialization activities in China.

NeoStem has also reached an agreement with the FDA to start Phase III trials of its Melapuldencel-T treatment for metastatic melanoma. (PR)

Comments (1)
  • Wetworks
    , contributor
    Comments (3) | Send Message
    $NBS just turned into a China Pharma play. Didn't see this one coming.
    13 May 2014, 09:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs